Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 44,000 restricted stock units to six newly hired employees under its 2022 Inducement Plan, effective June 1, 2026.
Rhea-AI Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 44,000 restricted stock units to six newly hired employees under its 2022 Inducement Plan, effective June 1, 2026.
The RSUs vest over four years, with 25% vesting on each annual anniversary, consistent with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
Details
News Market Reaction – ARQT
In the Jun 8 session, ARQT gained 1.46%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement RSUs granted
- 44,000 units
- Aggregate restricted stock units to new hires under 2022 Inducement Plan
- New employees
- 6 employees
- Recipients of inducement restricted stock units
- Vesting term
- 4 years
- RSUs vest over four years subject to continued employment
- Annual vesting rate
- 25 percent
- RSUs vest 25 percent on each annual anniversary
- Grant date
- June 1, 2026
- Grant date for inducement restricted stock units
Historical Context
-
Publication of expert consensus on genital psoriasis care.
-
Announcement of presentation at Goldman Sachs healthcare conference.
-
Disclosure of RSUs and options for 40 new hires.
-
Q1 2026 financials, ZORYVE revenue and full-year guidance.
-
sNDA submission for ZORYVE cream 0.05% in infants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 1, 2026, as a material inducement to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.